Vaccination against GIP for the Treatment of Obesity
2008

Vaccination Against GIP for the Treatment of Obesity

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): Fulurija Alma, Lutz Thomas A., Sladko Katja, Osto Melania, Wielinga Peter Y., Bachmann Martin F., Saudan Philippe

Primary Institution: Cytos Biotechnology AG, Schlieren, Switzerland

Hypothesis

Disrupting GIP signaling through vaccination may provide a novel therapeutic strategy for obesity treatment.

Conclusion

Vaccination against GIP was found to be safe and effective in reducing body weight gain in mice on a high fat diet.

Supporting Evidence

  • Vaccination with VLP-GIP induced high titers of specific antibodies.
  • Qβ-GIP vaccinated mice gained 35% less weight compared to controls.
  • Body fat content was reduced by 28% in vaccinated mice.
  • Vaccination did not affect glucose homeostasis in mice.

Takeaway

The study shows that a vaccine can help mice not gain as much weight when they eat a lot of fat, which might help people with obesity.

Methodology

Mice were vaccinated with GIP peptides attached to virus-like particles and monitored for body weight gain and antibody response.

Limitations

Further preclinical safety/toxicology studies are required before human trials can be considered.

Participant Demographics

C57BL/6 female mice, approximately 20 g, aged 8 weeks.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1371/journal.pone.0003163

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication